0001209191-20-060598.txt : 20201125
0001209191-20-060598.hdr.sgml : 20201125
20201125203145
ACCESSION NUMBER: 0001209191-20-060598
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201123
FILED AS OF DATE: 20201125
DATE AS OF CHANGE: 20201125
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kalowski Lee
CENTRAL INDEX KEY: 0001618273
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38916
FILM NUMBER: 201352547
MAIL ADDRESS:
STREET 1: C/O TOKAI PHARMACEUTICALS, INC.
STREET 2: ONE BROADWAY, 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS plc
CENTRAL INDEX KEY: 0001761612
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
BUSINESS ADDRESS:
STREET 1: B900 BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
BUSINESS PHONE: 011441223261503
MAIL ADDRESS:
STREET 1: B900 BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
FORMER COMPANY:
FORMER CONFORMED NAME: BICYCLE THERAPEUTICS Ltd
DATE OF NAME CHANGE: 20181212
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-11-23
0
0001761612
BICYCLE THERAPEUTICS plc
BCYC
0001618273
Kalowski Lee
C/O BICYCLE THERAPEUTICS PLC
B900, BABRAHAM RESEARCH CAMPUS
CAMBRIDGE
X0
CB22 3AT
UNITED KINGDOM
0
1
0
0
President and CFO
Ordinary Shares
2020-11-23
4
M
0
17189
1.56
A
17189
D
Ordinary Shares
2020-11-23
4
S
0
16976
19.82
D
213
D
Ordinary Shares
2020-11-23
4
S
0
213
20.38
D
0
D
Ordinary Shares
2020-11-25
4
M
0
9781
1.56
A
9781
D
Ordinary Shares
2020-11-25
4
S
0
9781
20.07
D
0
D
Stock Option (Right to Buy)
1.56
2020-11-23
4
M
0
17189
0.00
D
2027-07-23
Ordinary Shares
17189
122585
D
Stock Option (Right to Buy)
1.56
2020-11-25
4
M
0
9781
0.00
D
2027-07-23
Ordinary Shares
9781
112804
D
Shares exercised and sold pursuant to a Rule 10b5-1 trading plan.
This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.33651 to GBP 1.00 as of November 23, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.24 to $20.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4) and (6).
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.24 to $20.50 inclusive.
This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.33434 to GBP 1.00 as of November 25, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.24 inclusive.
20% of the shares subject to the option vested on July 24, 2018, 60% of the shares subject to the option will vest each month thereafter in 36 equal monthly installments, and the remaining 20% of the shares subject to the option will vest on the earlier of (i) the fourth anniversary of the grant date and (ii) the date on which the Issuer's board of directors determines that the Issuer has satisfied certain performance vesting milestones, in all cases provided that the Reporting Person remains continuously employed with us through each applicable vesting date.
/s/ Lee Kalowski
2020-11-25